Skip to main content
ARS Home » Northeast Area » Orient Point, New York » Plum Island Animal Disease Center » Foreign Animal Disease Research » Research » Research Project #420617


Location: Foreign Animal Disease Research

Project Number: 8064-32000-057-27-S
Project Type: Non-Assistance Cooperative Agreement

Start Date: Mar 1, 2011
End Date: Sep 30, 2015

The objective of this agreement is to develop a number of monoclonal antibodies specific for T cell derived cytokines in cattle and swine and to develop a series of monoclonal antibodies to bovine leukocyte antigen (BoLA) gene products in order to develop a rapid method to tissue type cattle. The specific objectives are: 1. Produce paired monoclonal antibodies to porcine cytokines IL-13 and IL-15. 2. Produce paired mononclonal antibodies to bovine cytokines IL-13, IL-15, IL-17 and IL-21. 3. Produce a collection of monoclonal antibodies that will differentially bind alleles of the BoLA Class I and Class II major histocompatibility complex (MHC) proteins that can be used to rapidly analyze blood samples and determine MHC gene expression in a given cow. Amendment 1: 4. Produce monoclonal antibodies to porcine immunoglobulins. Amendment 2: 5. Publish procedings from the 10th International Veterinary Immunolgy Symposium, Recent Developments in Veterinary Vaccinology conference, which was held August 28, 2013 in Milan, Italy, which featured new veterinary vaccines and vaccination strategies, including the development of major histocompatability tetramers for cattle and swine to correlate T cell responses with protection following vaccination. These developments were made possible, in part, by the generation of the monoclonal antibodies described above. (PA-13-013) Amendment 3: 6. Produce paired monoclonal antibodies to produce porcine cytokines IL-17a and IL-17f.

ARS, PIADC and Green Mountain Antibodies will exchange reagents and produce monoclonal antibodies to cattle and swine proteins. Genes encoded with specific proteins will be cloned into the replication defective human adenovirus 5 vector (huAd5). Animal trials (mice, rabbit, cattle and swine) will be conducted and subsequent protein analysis conducted. Mice will then be immunized with Ad5 vectors expressing the protein. Mice will be tested for production of antibody reactive with the protein and positive mice will be tested for antibody production. In vitro screening will be conducted and the proteins generated will be purified.